Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective

1. Driessen, M.T.
2. Whalen, J.
3. Seewoodharry Buguth, B.
4. Vallejo-Aparicio, L.A.
5. Naya, I.P.
6. Asukai, Y.
7. Alcázar-Navarrete, B.
8. Miravitlles, M.
9. García-Río, F.
10. Risebrough, N.A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1186/S12931-018-0916-7 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus